SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it has accepted enrollment of a Hepatitis C (HCV) infected patient who will initiate a 30-day treatment case study of the Aethlon Hemopurifier® in the coming week. The Hemopurifier® is a first-in-class medical device that assists the immune response in combating infectious disease through real-time therapeutic filtration of infectious viruses and immunosuppressive proteins. In addition to being HCV infected, the enrolled patient suffers from end-stage renal disease (ESRD) requiring regular kidney dialysis treatment. The study goal is to demonstrate the Aethlon Hemopurifier® is able to inhibit HCV proliferation in an infected ESRD patient. The study design calls for 12 Hemopurifier® treatments to be administered during normally scheduled dialysis. As a result, four-hour Hemopurifier® treatments will be administered thrice weekly over a period of 30 days. The study is being conducted at the Fortis Hospital in Delhi, India.
